Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px
Document › Details

Redx Pharma plc (in administration). (6/22/17). "Press Relase: Update on Suspension of Trading".

Organisations Organisation Redx Pharma plc (AIM: REDX)
  Group Redx Pharma (Group)
  Organisation 2 FRP Advisory LLP
Products Product drug development
  Product 2 legal services
     


Redx, the drug discovery and development company, is today providing an update on developments since the announcement of the suspension of its shares from trading on the AIM market of the London Stock Exchange and the appointment of Jason Baker and Miles Needham of FRP Advisory LLP as joint administrators (the "Joint Administrators") on 24 May 2017.

The Joint Administrators are working with the Company's advisers on proposals to rescue Redx and return the Company to the control of its directors, with the intention of lifting the suspension and restoring trading in the ordinary shares.

Discussions regarding these proposals are at a relatively early stage and there can be no guarantee that these will be concluded successfully in the short term.

A further announcement will be made in due course, as and when appropriate.


For further information, please contact:

Redx Pharma Plc (in administration)
Contact for the Joint Administrators:
James Rossiter (Morgan Rossiter)
T: + 44 203 195 3240
Cantor Fitzgerald Europe (Nomad & Broker)
T: +44 20 7894 7000
Phil Davies/ Michael Reynolds
WG Partners LLP (Joint Broker)
T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson


About Redx Pharma Plc (in administration)
Company website: redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

   
Record changed: 2017-08-04

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for Redx Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px